Market Overview

CEL-SCI Says NYSE MKT Approves Plan to Return Co. to Listing-Standards Compliance

Related CVM
CEL-SCI Quarterly Patient Enrollment In Its Head And Neck Cancer Phase III Trial Increases Eight Fold Over Same Prior Year Period
CEL-SCI Enrolls 22 Patients During October In Its Phase III Immunotherapy Head And Neck Cancer Trial

CEL-SCI Corporation (NYSE: CVM) announces that the NYSE MKT (the “Exchange”) has accepted the Company's plan to bring itself into compliance with the Exchange's continued listing standards.

The Company previously received notice from the Exchange on July 18, 2013, indicating that the Company is not in compliance with Section 1003(a)(iv) of the Exchange's continued listing standards in the Company Guide. The Company was afforded the opportunity to submit a plan to regain compliance, and on August 19, 2013 the Company submitted its plan to the Exchange.

Posted-In: News

 

Related Articles (CVM)

Around the Web, We're Loving...

Get Benzinga's Newsletters